Video

Data Diversity Initiative: Tackling the Medical Research Data Gap

The data-gap in medical research is well documented, and has serious implications for large sections of the world’s population.

Diseases, treatments and drugs affect people differently according to factors such as race, ethnicity, gender or age, meaning these data gaps in research drastically limit our knowledge to effectively diagnose and treat disease. In the age of digital health, the data-gap can no longer be overlooked if we are to avoid exacerbating existing health inequalities.  

At BenevolentAI, we launched an internal initiative to address this challenge, raise awareness and brainstorm possible solutions to the data diversity problem. We then broadened our scope by engaging with the wider scientific and research community.  

During our inaugural event, we invited a panel of experts to discuss the problem of diversity in medical data, and then invited our audience to participate in an interactive workshop to brainstorm holistic and concrete solutions:  

  • Maria Nelson, Senior Head of Innovation Practice, Digital Catapult  
  • Jackie Hunter, CE Clinical and Strategic Partnerships BenevolentAI  
  • Rob Wilson, Senior Regulatory Consultant, DLRC  
  • Diane Harbison, CEO Decipher Analytics  
  • Dawn Duhaney, Product Manager, Wellcome Trust


More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021